BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Biologics

Genomics England Partners with QIAGEN to Deliver Pioneering Whole-Genome Sequencing Study for Newborns

Genomics England select QIAGEN’s Clinical Knowledge Base to power first-of-its-kind whole-genome sequencing study for newborns National stud...

January 08, 2025 | News

Asieris Pharmaceuticals Partners with CDC for Investigational Use of APL-1202 in Fatal Free-Living Amoebae Infections

Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary t...

January 07, 2025 | News

WuXi Biologics Partners with Candid Therapeutics in $925M Deal to Advance Trispecific T-Cell Engagers

WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced an agreemen...

January 07, 2025 | News

Astellas Pharma Announces NMPA Approval of Zolbetuximab in China for Advanced Gastric and GEJ Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the National Medical Products Administration (N...

January 06, 2025 | News

JCR Pharmaceuticals and Modalis Therapeutics Advance CNS Gene Therapy Collaboration

JCR Pharmaceuticals Co., Ltd. and Modalis Therapeutics Corporation announced that they have validated the initial proof of concept in a jo...

January 06, 2025 | News

Chime Biologics and Mabgeek Achieve Major Milestone with PPQ Completion for MG-K10 Antibody

Process Performance Qualification (PPQ) validates robust manufacturing standards and is crucial for regulatory compliance Marks a key step forward for t...

January 06, 2025 | News

Capricor Therapeutics Submits BLA for Deramiocel, Poised to Become First Approved Therapy for DMD Cardiomyopathy

If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone pay...

January 03, 2025 | News

European Commission Approves Amivantamab Plus Lazertinib for First-Line Treatment of EGFR-Mutated NSCLC

Janssen-Cilag International NV, a Johnson & Johnson company,announced the European Commission (EC) approval for a Type II variation indication extensio...

January 03, 2025 | News

Innovent Biologics and Roche Forge Strategic Alliance to Advance DLL3-Targeted ADC for Small Cell Lung Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

January 02, 2025 | News

Brii Biosciences Gains Full Control of BRII-179 Intellectual Property in $18M Deal

Further secures Brii's rights in BRII-179 with full control of intellectual property, future manufacturing and supply Several combination treatment studie...

January 01, 2025 | News

Radiopharm and Lantheus Join Forces to Advance Radiopharmaceutical Clinical Development in Australia

RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1 imaging t...

December 31, 2024 | News

CARsgen's Satricabtagene Autoleucel Achieves Positive Phase II Results in Advanced Gastric Cancer

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic mal...

December 31, 2024 | News

I Peace Achieves Milestone of Manufacturing 100 GMP-Grade iPS Cell Lines

Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the n...

December 31, 2024 | News

BeiGene Exercises Exclusive Option for DualityBio's B7H4 ADC, Paving the Way for Global Development

Duality Biologics ("DualityBio") announced that, BeiGene. Ltd. has exercised its exclusive option for the B7H4 antibody-drug conjugate (ADC) DB1312/BG-C907...

December 31, 2024 | News

Stay Connected